Power of two : combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer

Copyright © 2020 Elsevier B.V. All rights reserved..

Cancer research of the Warburg effect, a hallmark metabolic alteration in tumors, focused attention on glucose metabolism whose targeting uncovered several agents with promising anticancer effects at the preclinical level. These agents' monotherapy points to their potential as adjuvant combination therapy to existing standard chemotherapy in human trials. Accordingly, several studies on combining glucose transporter (GLUT) inhibitors with chemotherapeutic agents, such as doxorubicin, paclitaxel, and cytarabine, showed synergistic or additive anticancer effects, reduced chemo-, radio-, and immuno-resistance, and reduced toxicity due to lowering the therapeutic doses required for desired chemotherapeutic effects, as compared with monotherapy. The combinations have been specifically effective in treating cancer glycolytic phenotypes, such as pancreatic and breast cancers. Even combining GLUT inhibitors with other glycolytic inhibitors and energy restriction mimetics seems worthwhile. Though combination clinical trials are in the early phase, initial results are intriguing. The various types of GLUTs, their role in cancer progression, GLUT inhibitors, and their anticancer mechanism of action have been reviewed several times. However, utilizing GLUT inhibitors as combination therapeutics has received little attention. We consider GLUT inhibitors agents that directly affect glucose transporters by binding to them or indirectly alter glucose transport by changing the transporters' expression level. This review mainly focuses on summarizing the effects of various combinations of GLUT inhibitors with other anticancer agents and providing a perspective on the current status.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:1874

Enthalten in:

Biochimica et biophysica acta. Reviews on cancer - 1874(2020), 2 vom: 20. Dez., Seite 188457

Sprache:

Englisch

Beteiligte Personen:

Tilekar, Kalpana [VerfasserIn]
Upadhyay, Neha [VerfasserIn]
Iancu, Cristina V [VerfasserIn]
Pokrovsky, Vadim [VerfasserIn]
Choe, Jun-Yong [VerfasserIn]
Ramaa, C S [VerfasserIn]

Links:

Volltext

Themen:

Antineoplastic Agents
Cancer
Combination strategy
Drug synergy
GLUT inhibitors
Glucose Transport Proteins, Facilitative
Glucose transporters (GLUTs)
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Anmerkungen:

Date Completed 18.01.2021

Date Revised 12.11.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.bbcan.2020.188457

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM316650234